Randomised findings on CT-based follow-up after resection of early NSCLC

Regarding the optimal follow-up after surgery for early-stage NSCLC, the ESMO guidelines recommend patient surveillance every six months for 2-3 years with visits including history, physical examination and preferably contrast-enhanced spiral chest CT at 12 and 24 months [1]. Thereafter, annual visits including history, physical examination and chest CT should be performed to detect second primary tumours (SPCs). However, these recommendations are not based on randomised trials and therefore only have a low-to-moderate level of evidence.
The multi-centre phase III IFCT-0302 trial was the first large randomised study on follow-up after surgery for NSCLC and the first randomised trial to evaluate the interest of chest CT [2]. It compared minimal follow-up (Min), consisting of clinical visits with history and physical examination, chest x-ray and CT scan only in case of symptoms or abnormal chest x-ray, with maximal follow-up (Max). Max included history and physical examination as well as chest x-ray, but also contrast-enhanced CT scan of the thorax and upper abdomen. Fiberoptic bronchoscopy was mandatory for squamous and large-cell carcinomas.
In both arms, patients completed follow-up every six months for two years, followed by annual visits. A total of 1,775 patients with clinical stage I, II, or IIIA and T4 N0-2 NSCLC were enrolled within eight weeks after anatomic complete resection. Overall survival was defined as the primary endpoint.
After a median follow-up of 8 years and 10 months, OS did not differ signifi­cantly between the two arms (123.6 and 99.7 months with Max and Min, respectively; HR, 0.94; p = 0.37). At eight years, 54.6 % vs. 51.7 % of patients were alive. There was a trend for a shorter disease-free survival in the Max cohort (59.2 months vs. not reached; p = 0.07), which reflects earlier detection of recurrence and SPCs by CT scan. According to an exploratory analysis, patients experiencing relapses or SPCs at 24 months achieved the same median OS with both surveillance strategies, whereas CT-based surveillance significantly improved OS in those without recurrence or SPCs at 24 months.
The authors concluded that CT scans every six months are probably of no value during the first two years after surgery, but annual chest scans might be useful in the long term. Patients at high risk for SPCs that are potentially amenable to curative treatment can experience long-term benefits.

References

  1. Vansteenkiste J et al., 2nd ESMO Consensus Conference on Lung Cancer. early stage non-small cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014; 25(8): 1462-74
  2. Westeel V et al., Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC) NCT001983431. ESMO 2017, abstract 1273O

More posts

ALK-positive NSCLC: updates on crizotinib and alectinib

PROFILE 1014 was the first study to define the role of the ALK inhibitor crizotinib in the first-line treatment of patients with ALK-positive lung cancer. It compared crizotinib 250 mg twice daily (n = 172) with pemetrexed plus cisplatin (n = 171) in patients with ALK-positive, locally advanced, recurrent or metastatic non-squamous NSCLC in the first-line setting.

Characteristics and outcomes for SCLC arising from transformation

A low but significant proportion of EGFR-mutant adenocarcinomas transforms to SCLC at the time of acquisition of resistance to EGFR TKI therapy. Moreover, cases of de novo SCLC harbouring EGFR mutations have been reported. As the clinical characteristics and clinical course of SCLC-transformed EGFR-mutant lung cancer are largely unknown, Marcoux et al. retrospectively reviewed the records of 16 patients with EGFR-mutant SCLC treated between 2006 and 2017.

Reaching unprecedented outcome dimensions in malignant mesothelioma

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer with poor prognosis. While combination chemotherapy with platinum and pemetrexed with or without bevacizumab is a standard in first-line treatment, no approved second-line strategies have been established to date. Gemcitabine or vinorelbine are often used in this situation, but these only show limited activity.

Interview: “Survival is the result of multiple treatment lines”

FLAURA is a positive trial, as its results favour osimertinib over gefitinib and erlotinib. Now we have to consider this among the multiple options that are available for the first-line treatment of EGFR-mutant lung cancer. Besides osimertinib, there are the first-generation TKIs erlotinib and gefitinib and the se­cond-generation TKI afatinib, but maybe sometime soon also dacomitinib, for which data were presented at the last ASCO Meeting.

EGFR-mutant lung cancer: sequencing as a major topic in light of new data

The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) erlotinib and gefitinib as well as the second-generation EGFR TKI afatinib are the recommended first-line options for patients with EGFR-mutant NSCLC. Regardless of the extent of initial response, however, more than 60 % of patients develop the T790M resistance mutation.

Randomised findings on CT-based follow-up after resection of early NSCLC

Regarding the optimal follow-up after surgery for early-stage NSCLC, the ESMO guidelines recommend patient surveillance every six months for 2-3 years with visits including history, physical examination and preferably contrast-enhanced spiral chest CT at 12 and 24 months. Thereafter, annual visits including history, physical examination and chest CT should be performed to detect second primary tumours (SPCs).